menu
    • menu
    [{"orgOrder":0,"company":"Handa Pharmaceuticals","sponsor":"Cycle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Dasatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Handa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Handa Pharmaceuticals \/ Cycle Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Handa Pharmaceuticals \/ Cycle Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Handa Pharmaceuticals

    Menu

    Handa Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Handa Pharmaceuticals

                            Taiwan arrow
                            AGGSpend
                            Not Confirmed

                            Handa Pharmaceuticals

                            Taiwan arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Cycle Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) Tablets

                            Details : Under the licensing agreement, Cycle will be responsible for the commercialization of Phyrago (dasatinib), an FDA approved drug for treating two types of leukemia, Ph+ CML and Ph+ ALL.

                            Product Name : Phyrago

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 21, 2025

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Cycle Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth